ES 7604 tagged 2x's, then move up..

Looks ready for another move higher

Nice pre market volume, and up nearly 7%

Just hit 52 weekr

Looks like its flaggin'

Not working out so well...   

Bought a bit more Hive ahead of earnings..we’ll see.

Stock at $2.07 now.  Up 35% in 5 days. Its garbage, but working...(until it doesn't)

Supply zone approaching

I'm buying puts soon

$1.72 in after hours. Opened today at .72.

FATE 05/21/2026 08:30AM ET Globe Newswire

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026.

Presentation details are as follows:

ASCO – American Society of Cancer Oncology

Product Candidate: FT836

Title: Preliminary Phase 1 Results of a MICA/B-targeted CAR T-cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy

Session: Developmental Therapeutics—Immunotherapy

Poster Presentation Date / Time: Saturday, May 30 ^th, 1:30-4:30 CT.

A link to the abstract can be found here: ASCO FATE

EULAR - European Congress of Rheumatology

Product Candidate: FT819

Title: Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge

Session: Clinical Poster Tours: From pathway to patient – therapeutic advances in Lupus (POS0079)

Poster Tour Date / Time: Thursday, June 4 ^th, 9:30 a.m. BST

A link to the abstract can be found here: EULAR FATE

Product Candidate: FT839

Title: Off-the-Shelf Dual-CAR T-Cell Therapy: Targeting B and T Cells in Autoimmune Disease Without Preconditioning

Session: Basic Abstract Sessions: New therapeutic targets in Rheumatoid Arthritis and Sjogren's (OPO156)

Oral Presentation Date / Time: Thursday, June 4 ^th, 8:15 a.m. BST

A link to the abstract can be found here: EULAR FATE

Micro cap Biotech I have shares in now pivoting to a space company..go figure.. ha. Symbol changes tomorrow to RKTO. Up big this am but will fade I’m sure. One to watch tho.

Our DXYZ is cratering

Long time holder (sufferer), hope so. But they still 1-2 yrs from legit rev’s.

Averaged in today with the recent pull back. I see it at $9.50-10 this year.

I limped back in...looks like ready for another move.   

RONB is another I believe that has spacex too (same family of funds). But DO check.

Anyone believe that wave b is ending..?

Love these maps kalkgrun